INSULET CORPORATION for INSULET CORPORATION
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to talks of future budget reconciliation package. Issues related to the reintroduction of the DIABETES Act (S.4037) in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade and the Sec. 232 Tariff investigation related to Medical Devices. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to National Coverage Determination revisions specifically in reference to durable infusion insulin pumps. Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act. Issues related to CMS finalized rule, DMEPOS Home Health Rule. Issues related to expansion of Competitive Bidding Program and implementation of CMS finalized rule relating to DMEPOS Home Health Rule. Issues related to wearable health care devices.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AL LYTTON New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.